Efficacy of HPA-1a (PlA1)-negative platelets in a patient with post-transfusion purpura

American Journal of Hematology

Volumn 76, Issue 3, 2004, Pages 258-262

  Loren, Alison Wakoff ^a,b   Abrams, Charles S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antigens; Human platelet; Platelet transfusion; Post transfusion purpura

Indexed keywords

HUMAN PLATELET ANTIGEN 1A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD TRANSFUSION REACTION; BRAIN HEMORRHAGE; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IMMUNOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; THROMBOCYTE TRANSFUSION;

AGED; AGED, 80 AND OVER; ANTIGENS, HUMAN PLATELET; BLOOD PLATELETS; CEREBRAL HEMORRHAGE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; PLATELET TRANSFUSION; PURPURA;

EID: 3042595830     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20093     Document Type: Article

References (60)

1. nd edition. Baltimore: Williams & Wilkins; 1998. Chapter 28, p 599.
2. rd edition. New York: Churchill-Livingstone; 2000. Chapter 126, p 2096.
3. th edition. New York: McGraw-Hill Health Publications Division; 2001. Chapter 117, p 1495.
4. A1-negative platelet transfusion. Am J Hematol 1979;6:71.
5. Waters AH. Post-transfusion purpura. Blood Rev 1989;3:83.
6. van Leeuwen EF, von dem Borne AE, von Riesz LE, et al. Absence of platelet-specific alloantigens in Glanzmann's thrombasthenia. Blood 1981;57:49.
7. Kunicki TJ, Aster RH. Deletion of the platelet-specific alloantigen PlA1 from platelets in Glanzmann's thrombasthenia. J Clin Invest 1978;61:1225.
8. Kunicki TJ, Aster RH. Isolation and immunologic characterization of the human platelet alloantigen, PlA1. Mol Immunol 1979;16:353.
9. Newman PJ, Martin LS, Knipp MA, Kahn RA. Studies on the nature of the human platelet alloantigen, PlA1: localization to a 17,000-dalton polypeptide. Mol Immunol 1985;22:719.
10. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens. PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778.
11. Newman PJ, Valentin N. Human platelet alloantigens: recent findings, new perspectives. Thromb Haemost 1995;74:234.
12. Vogelsang G, Kickler TS, Bell WR. Post-transfusion purpura: a report of five patients and a review of the pathogenesis and management. Am J Hematol 1986;21:259.
13. Mueller-Eckhardt C. Post-transfusion purpura. Br J Haematol 1986;64:419.
14. Zeigler Z, Murphy S, Gardner FH. Post-transfusion purpura: a heterogeneous syndrome. Blood 1975;45:529.
15. Boizard B, Wautier JL. Lek a, a new platelet antigen absent in Glanzmann's thrombasthenia. Vox Sang 1984;46:47.
16. a. Am J Hematol 1986;21:79.
17. Taaning E, Morling N, Ovesen H, Svejgaard A. Post transfusion purpura and anti-Zwb (-PlA2). Tissue Antigens 1985;26:143.
18. Lucas GF, Pittman SJ, Davies S, et al. Post-transfusion purpura (PTP) associated with anti-HPA-1a, anti-HPA-2b and anti-HPA-3a antibodies. Transfus Med 1997;7:295.
19. Anolik JH, Blumberg N, Snider J, Francis CW. Posttransfusion purpura secondary to an alloantibody reactive with HPA-5a (Br(b)), Transfusion 2001;41:633.
20. McFarland JG. Platelet immunology and alloimmunization. In: Rossi EC, Simon TL, Moss GS, Gould SA, editors. Principles of transfusion medicine, Bethesda, MD: Williams & Wilkins; 1996. p 233.
21. Glud TK, Rosthoj S, Jensen MK, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Scand J Haematol 1983;31:495.
22. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983;2:193.
23. Becker T, Panzer S, Maas D, et al. High-dose intravenous immunoglobulin for post-transfusion purpura. Br J Haematol 1985;61:149.
24. Berney SI, Metcalfe P, Wathen NC, Waters AH. Post-transfusion purpura responding to high dose intravenous IgG: further observations on pathogenesis. Br J Haematol 1985;61:627.
25. Hamblin TJ, Naorose Abidi SM, Nee PA, et al. Successful treatment of post-transfusion purpura with high-dose immunoglobulins after lack of response to plasma exchange. Vox Sang 1985;49:164.
26. Mueller-Eckhardt C, Kuenzlen E, Thilo-Korner D, Pralle H. High-dose intravenous immunoglobulin for post-transfusion purpura [letter]. N Engl J Med 1983;308:287.
27. Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988;57:163.
28. Abramson N, Eisenberg PD, Aster RH. Post-transfusion purpura: immunologic aspects and therapy. N Engl J Med 1974;291:1163.
29. Laursen B, Morling N, Rosenkvist J, et al. Post-transfusion purpura treated with plasma exchange by Haemonetics cell separator. A case report. Acta Med Scand 1978;203:539.
30. Lau P, Sholtis CM, Aster RH. Post-transfusion purpura: an enigma of alloimmunization. Am J Hematol 1980;9:331.
31. Lillicrap DP, Ford PM, Giles AR. Prolonged thrombocytopenia in post-transfusion purpura (PTP) associated with changes in the crossed immunoelectrophoretic pattern of von Willebrand factor (vWF), circulating immune complexes and endothelial cell cytotoxicity. Br J Haematol 1986;62:37.
32. Vincent EC, Willett T. Post-transfusion purpura [see comments]. J Am Board Fam Pract 1991;4:175.
33. Gonzalez J, Schwartz J, Gerstein G, Klainer AS, Bisaccia E. Case report: post-transfusion purpura. N J Med 1996;93:101.
34. Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apheresis 2000;15:28.
35. Kumar R, Ghali A, Ekaldious AW, et al. Post-transfusion purpura: case report. Ann Hematol 2001;80:488.
36. Weisberg LJ, Linker CA. Prednisone therapy of post-transfusion purpura. Ann Intern Med 1984;100:76.
37. Lippman SM, Lizak GE, Foung SK, Grumet FC. The efficacy of PlA1-negative platelet transfusion therapy in posttransfusion purpura. West J Med 1988;148:86.
38. Win N, Peterkin MA, Watson WH. The therapeutic value of HPA-1a-negative platelet transfusion in post-transfusion purpura complicated by life-threatening haemorrhage. Vox Sang 1995;69:138.
39. Win N, Matthey F, Slater GP. Blood components - transfusion support in post-transfusion purpura due to HPA-1a immunization [letter]. Vox Sang 1996;71:191.
40. A1-negative platelets. Transfusion 1990;30:433.
41. Kickler TS. The challenge of platelet alloimmunization: management and prevention. Transfus Med Rev 1990;4:8.
42. Kekomaki R. Use of HLA- and HPA-matched platelets in alloimmunized patients. Vox Sang 1998;74:359.
43. Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. Eur J Haematol 1998;60:112.
44. Pappalardo PA, Secord AR, Quitevis P, et al. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984.
45. Valentin N, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990;27:73.
46. L'Abbe D, Tremblay L, Filion M, et al. Alloimmunization to platelet antigen HPA-1a (PlA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum Immunol 1992;34:107.
47. Shulman NR, Aster RH, Leitner A, Hiller MC. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in "autoimmunity". J Clin Invest 1961;40:1597.
48. Taaning E, Tonnesen F. Pan-reactive platelet antibodies in post-transfusion purpura. Vox Sang 1999;76:120.
49. Forestier F, Hohlfeld P. Management of fetal and neonatal alloimmune thrombocytopenia. Biol Neonate 1998;74:395.
50. a) as determined by antenatal screening. Blood 1998;92:2280.
51. Cobos E, Gandara DR, Geier LJ, Kirmani S. Post-transfusion purpura and isoimmune neonatal thrombocytopenia in the same family. Am J Hematol 1989;32:235.
52. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997;337:22.
53. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995;90:655.
54. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989;1:363.
55. Valentin N, Visentin GP, Newman PJ. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 1995;85:3028.
56. McFarland JG. Alloimmunization and platelet transfusion. Semin Hematol 1996;33:315.
57. Murphy MF, Verjee S, Greaves M. Inadequacies in the postnatal management of fetomaternal alloimmune thrombocytopenia (FMAIT). Br J Haematol 1999;105:123.
58. Verran J, Grey D, Bennett J, et al. HPA-1, -3, -5 genotyping to establish a typed platelet donor panel. Pathology 2000;32:89.
59. Ranasinghe E, Walton JD, Hurd CM, et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001;113:40.
60. Lee K, Beaujean F, Bierling P. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002;117:482.